- When Should Systemic Myeloma Treatment Be Initiated?
- Individualized Approaches to Frontline Treatment Selection
- Transplantation, Consolidation, and Maintenance Strategies and the Role of MRD in Monitoring Treatment Response
- Therapeutic Strategies After First Relapse Following Initial Therapy
- Current Treatment Options for Patients With Late Relapse
- Current Supportive Care Strategies, Including Emerging Treatment Approaches for Myeloma-Related Bone Disease
Date / Time
carol huff, MD
Medical Director, Sidney Kimmel Comprehensive Cancer Center
Associate Professor of Medicine and Oncology
Multiple Myeloma Program
Johns Hopkins University
Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Jesus Berdeja, MD
Director of Multiple Myeloma Research
Sarah Cannon Research Institute
Sarah Cannon Center for Blood Cancer
Damian J. Green, MD
Clinical Research Division
Department of Medicine
Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance
Parameswaran Hari, MD, MS
Professor of Medicine
Medical College of Wisconsin
Section Head, Adult Blood and Marrow Transplant
Department of Hematology/Oncology
Froedtert & The Medical College of Wisconsin
Prashant Kapoor, MD
Assistant Professor of Medicine and Oncology
Department of Hematology
Ajay Nooka, MD
Division of Bone Marrow Transplant
Department of Hematology and Oncology
Winship Cancer Institute
Expert guidance on the latest treatment of multiple myeloma in 1-hour interactive meetings, with an associated downloadable slideset and PDF resource available on the CCO Web site to enhance the information presented at the live meetings.
The goal of this activity is to improve VHA clinicians’ competence in providing optimal care while considering the unique needs of veterans with multiple myeloma.
This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers who care for veterans with myeloma.
- Integrate timely systemic treatment for appropriate patients based on newly revised multiple myeloma diagnosis and staging criteria
- Plan individualized treatment strategies for patients with multiple myeloma through consideration of the available clinical data as well as risk assessment, comorbidities, and patient age/fitness and preferences
- Describe the efficacy and safety evidence of novel combination therapeutic regimens for patients with multiple myeloma
- Manage disease-related and treatment-related symptoms in patients with multiple myeloma
Physician Continuing Medical Education
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
1.0 contact hour may be earned for successful completion of this activity.
Provider approved by the California Board of Registered Nursing, Provider Number 13664, for 1.0 contact hour. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.
Pharmacist Continuing Education
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This program has been assigned ACPE Universal Activity 0797-9999-19-035-L01-P. This program is designated for up to 1.0 contact hour (0.10 CEUs) of continuing pharmacy education credit.
Type of Activity: Application
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.